WallStreetZenWallStreetZen

NASDAQ: GNFT
Genfit Sa Stock Forecast, Predictions & Price Target

Analyst price target for GNFT

Based on 1 analyst offering 12 month price targets for Genfit Sa.
Min Forecast
$11.00+222.58%
Avg Forecast
$11.00+222.58%
Max Forecast
$11.00+222.58%

Should I buy or sell GNFT stock?

Based on 1 analyst offering ratings for Genfit Sa.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GNFT stock forecasts and price targets.

GNFT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-05

1 of 1

Forecast return on equity

Is GNFT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is GNFT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

GNFT revenue forecast

What is GNFT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$103.5M+144.03%
Avg 2 year Forecast
$56.7M+33.68%
Avg 3 year Forecast
$91.2M+114.96%
GNFT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GNFT revenue growth forecast

How is GNFT forecast to perform vs Biotechnology companies and vs the US market?
Company
23.22%
Industry
38.03%
Market
10.06%
GNFT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GNFT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GNFT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GNFT$3.41$11.00+222.58%Buy
ATOS$1.37$4.00+191.97%Buy
CGEN$1.90$4.50+136.84%Strong Buy
IVA$3.33$22.33+570.66%Strong Buy
OBIO$4.64$17.00+266.38%Strong Buy

Genfit Sa Stock Forecast FAQ

Is Genfit Sa Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: GNFT) stock is to Buy GNFT stock.

Out of 1 analyst, 0 (0%) are recommending GNFT as a Strong Buy, 1 (100%) are recommending GNFT as a Buy, 0 (0%) are recommending GNFT as a Hold, 0 (0%) are recommending GNFT as a Sell, and 0 (0%) are recommending GNFT as a Strong Sell.

If you're new to stock investing, here's how to buy Genfit Sa stock.

What is GNFT's revenue growth forecast for 2024-2026?

(NASDAQ: GNFT) Genfit Sa's forecast annual revenue growth rate of 23.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Genfit Sa's revenue in 2024 is $41,495,652.On average, 2 Wall Street analysts forecast GNFT's revenue for 2024 to be $5,158,419,090, with the lowest GNFT revenue forecast at $4,937,650,116, and the highest GNFT revenue forecast at $5,379,188,065. On average, 2 Wall Street analysts forecast GNFT's revenue for 2025 to be $2,825,892,711, with the lowest GNFT revenue forecast at $2,009,844,864, and the highest GNFT revenue forecast at $3,641,940,558.

In 2026, GNFT is forecast to generate $4,543,953,750 in revenue, with the lowest revenue forecast at $4,123,844,843 and the highest revenue forecast at $4,964,062,657.

What is GNFT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GNFT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is GNFT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year GNFT price target, the average GNFT price target is $11.00, with the highest GNFT stock price forecast at $11.00 and the lowest GNFT stock price forecast at $11.00.

The Wall Street analyst predicted that Genfit Sa's share price could reach $11.00 by Apr 5, 2025. The average Genfit Sa stock price prediction forecasts a potential upside of 222.58% from the current GNFT share price of $3.41.

What is GNFT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GNFT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.